AI in Medicine — Cancer & Rare Disease — 2026-09-24 (Thu)

Latest news on AI and cancer treatment

Overview

There were reports on the results of large-scale trials in breast cancer screening AI (image diagnosis), followed by the incorporation of AI into oncology EHRs and the presentation of collaborations and clinical data in the drug discovery field (AbbVie x Iambic, Insilico). On the regulatory front, the FDA has granted breakthrough device designation to chest X-ray triage AI.

Breast cancer

The details of the study size (randomized or observational study, etc.) are not clear from the headline alone. - A report that a wearable AI breast cancer screening device has entered the final clinical trial stage (Inshorts), and a report that Lord's Mark Industries' AI breast cancer screening device has received approval for final clinical trials (Ahmedabad Mirror). In both cases, detailed study design and target size are not listed in the headings. - Article by Sherene Loi (Expert) discussing what AI can add to tumor-infiltrating lymphocyte (TIL) assessment in breast cancer (Oncodaily).

lung cancer

- Research report (diagnosticimaging.com) showing that AI bone mineral density (BMD) assessment using chest CT was associated with progression of cognitive decline and white matter changes on brain MRI. The subject, phase, and whether it is facing forward or backward are not stated in the heading. - Interview article (HCPLive) with Dr. Alvar Agusti (MD, PhD) about the use of AI in COPD diagnosis, treatment disparities, and blank areas of guidelines.

Malignant brain tumor

No relevant information (Lokahi's AI asset discovery platform's acquisition of external clients is a drug discovery platform topic and not brain tumor-specific clinical information, so it is not covered).

Leukemia/lymphoma

No applicable information.

Colon cancer/digestive organ

- Report on a new AI tool to rapidly measure the quality of colonoscopies (EIN News). Details such as trial stage and number of target facilities are not listed in the heading.

Rare cancer

- Transition Bio receives $750,000 grant to use AI drug discovery platform to target Ewing's sarcoma-related proteins, which are considered "undruggable" (Business Weekly). Estimated to be in preclinical stage, but not specified in the heading. - Report on a new evaluation framework to examine the hidden risks of medical language model (LLM) "AI doctors" (Bioengineer.org). It is unclear from the headline whether the content is specific to rare cancers such as adenoid cystic carcinoma.

Diagnosis/Pathology/Image

- FDA grants Breakthrough Device Designation to chest X-ray (CXR) triage AI software for pneumomediastinum/lung collapse (diagnosticimaging.com). - Report that AI improves detection of incidental pulmonary embolism in CT images (EMJ). Details of the study design are not listed in the heading. - Opinion article (The New York Times) in which Jensen Huang (presumed to be NVIDIA CEO, but title not listed in the headline) discusses AI pessimism. - Verda raises $189 million in Series B, becoming the first European AI cloud company to reach unicorn valuation (Wowtale). Direct relationship to cancer field is not mentioned in the heading. - Coverage of Tempus AI's pricing strategy and data growth (TradingView). Since the content is related to stocks and business results, details are omitted in this report.

Treatment selection/drug discovery

- Oracle launches electronic health record (EHR) for oncology that incorporates AI (HCI Innovation Group, Unite.AI, Japanese version Unite.AI). - Insilico Medicine plans to present First-in-Human data of the AI-designed Pan-TEAD inhibitor "ISM6331" at ESMO 2026 (Insilico Medicine). The data appears to be the first human administration data equivalent to Phase I, but the target cancer type and specific phase (Phase I, etc.) are not specified in the heading. - AbbVie and Iambic form a partnership to accelerate AI drug discovery (Indian Pharma Post, AIM Media House). This appears to be a drug discovery partnership at the preclinical stage.

Regulations/Approval

- FDA: Grants "Breakthrough Device Designation" to AI chest X-ray triage software for pneumomediastinum/lung collapse (diagnosticimaging.com). Item name is not listed in the heading. - No applicable information regarding EMA/PMDA.

Clinical trial implementation status

Specific trial names, NCT numbers, and registration status from ClinicalTrials.gov are not included in the information provided. The clinical trial-related developments mentioned in the news headlines are as follows (cannot be confirmed as primary information on ClinicalTrials.gov). - There are reports that an AI breast cancer screening wearable device is in the final clinical trial stage (Inshorts, Ahmedabad Mirror). The trial name, NCT number, and number of participants are unknown. - First-in-Human data for Insilico Medicine's ISM6331 is scheduled to be presented at ESMO 2026 (target cancer types and NCT numbers are not listed in the headline). *No estimates will be made regarding the number of cases or registration status.

Japanese movements

- Oracle's announcement of an oncology EHR equipped with embedded AI for cancer treatment was also reported in Japanese media (Unite.AI Japanese version). - Lokahi's first external client acquisition for its AI drug discovery platform was reported in a Japanese financial media (Investing.com Japanese version). Specific reports on the introduction of AI in domestic medical institutions are not included in the headlines.

Remarks from VIPs

- Sherene Loi: Discussed what AI can add to tumor-infiltrating lymphocyte (TIL) assessment in breast cancer (title details not listed in headline, Oncodaily). - Alvar Agusti (MD, PhD): Responded to an interview regarding the use of AI in COPD diagnosis, treatment disparities, and gaps in guidelines (HCPLive). - Jensen Huang: Opinion that AI pessimism (alarmism) has gone too far (title not listed in headline, The New York Times, opinion article).

The list of important people being tracked is blank, so in Section 13 above, only the people who appeared in the headings are listed.

Latest news on AI and rare and incurable diseases

Overview

This time's headlines do not involve direct progress regarding diagnostic and therapeutic drugs for designated intractable diseases, but instead focus on the stock and investment trends of a genome analysis company (Tempus AI), Anthropic's research funding and establishment of a biological research institute, AI image analysis of ANCA-associated vasculitis (AAV), and an AI drug discovery company's academic conference presentation plans for TEAD inhibitors. In terms of systems, there is only one report regarding Anthropic's investment in the rare disease field.

Diagnosis of rare diseases

No applicable information

Gene analysis/genome

Multiple headings about Tempus AI (TEM). Growth prospects for the stock price and data business (TradingView article) and stock sales by executives (through a preset trading plan, two Stock Titan articles) have been reported, but these are all about corporate finances and stock trends, and the headlines do not include specific figures or results regarding the content of genetic analysis technology or its application to rare disease diagnosis. There are reports that Anthropic has invested an additional A$10 million (cumulative total of A$13 million) in scientific research in Australia, but the link to the targeted field and rare diseases cannot be confirmed from the headline.

Development of therapeutic drugs

Insilico Medicine announced that it plans to present first-in-human data for its AI-designed Pan-TEAD inhibitor "ISM6331" at the ESMO 2026 conference. The stage is a preview of the data announcement of the first human administration study (equivalent to Phase I), and the contents of the efficacy and safety results are not indicated in the headline. The target disease (type of cancer, etc.) is also unclear from the headline.

Nerve/muscular diseases

No applicable information

Immunology/Collagen disease

It is reported that organ damage patterns in ANCA-associated vasculitis (AAV) have been classified into four different subtypes through image and clinical data analysis using AI (ANCA Vasculitis News). The number of facilities targeted for the study, the number of cases, and whether it was a single facility or multiple facilities are not stated in the heading, so it is unclear. The disease group included in ANCA-related vasculitis (microscopic polyangiitis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, etc.) is included in the immune disease group on the list of intractable diseases designated by the Ministry of Health, Labor and Welfare, but it is not possible to determine from the headline which disease this report is targeting.

Rare metabolic/endocrine diseases

No applicable information

System/Patient Support

It was reported that Anthropic will establish a biology laboratory in the United States and focus its drug discovery efforts on preclinical research and rare diseases (biz.chosun.com). The specific support system, subsidy details, and target diseases are not indicated in the heading. There is no relevant information regarding reports regarding Japan's medical expenses subsidies, intractable disease law, research groups, and patient associations.

Japanese movements

There is a headline of a market research report (forecast for 2026-2033) regarding the Causal AI market, but the link to the rare disease field and specific initiatives in Japan cannot be confirmed from the headline.

Remarks from VIPs

No applicable information